Globenewswire·2026-03-13 18:45Core Viewpoint - Rosen Law Firm has announced a class action lawsuit on behalf of purchasers of Nektar Therapeutics securities during the specified Class Period, indicating potential legal issues for the company and its investors [1]. Group 1: Class Action Details - The class action lawsuit is for purchasers of Nektar securities between February 26, 2025, and December 15, 2025 [1]. - Investors who purchased Nektar securities during the Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must move the Court by May 5, 2026, to represent other class members in the litigation [3]. Group 2: Legal Representation - Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [4]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019 and has been ranked highly for its performance in securities class action settlements [4]. Group 3: Case Allegations - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [5]. - The claims suggest that these misrepresentations led to investor damages when the true details became public [5].